KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'

By: via Benzinga
On Monday, KemPharm Inc (NASDAQ: KMPH) reported encouraging results from its exploratory Phase 1 study assessing the pharmacokinetics, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.